-
1.发明授权
公开(公告)号：KR101226669B1
公开(公告)日：2013-01-25
申请号：KR1020080092366
申请日：2008-09-19
Applicant: 한올바이오파마주식회사
IPC: C07C279/26 , C07C279/20 , C07C55/14
CPC classification number: C07C279/26 , C07C55/08 , C07C55/12 , C07C55/14 , C07C59/245
Abstract: 본 발명은 N,N-디메틸 이미도디카르본이미딕 디아미드의 신규한 디카르복실산염, 그의 제조방법 및 그의 약제학적 조성물에 관한 것이다. 더욱 상세하게는 N,N-디메틸 이미도디카르본이미딕 디아미드와 특정한 디카르복실산을 반응시켜 제조한 결정성 산부가염에 관한 것으로서 용해도, 안정성, 비흡습성, 부착방지특성 등의 물리화학적 성질이 더욱 개선될 뿐 아니라 독성이 낮아, 당뇨 및 당뇨병, 비만증, 고지혈증, 지방간, 관상 동맥 질환, 골다공증, 다낭성 난소증후군 등이 복합적으로 나타나는 이른바 대사성 증후군을 지닌 자들의 당뇨병 및 그의 합병증, p53 유전자가 결여된 암, 근육통, 근육세포독성 및 횡문근 융해 등의 예방 또는 치료에 필요한 N,N-디메틸 이미도디카르본이미딕 디아미드의 신규한 디카르복실산염, 그의 제조방법과 그의 약제학적 조성물에 관한 것이다.
메트포르민, 디카르복실산염, 아디핀산, 글루타르산, 말론산, 사과산, 당뇨병-
公开(公告)号：KR1020090114320A
公开(公告)日：2009-11-03
申请号：KR1020090037372
申请日：2009-04-29
Applicant: 한올바이오파마주식회사
CPC classification number: A61K45/06
Abstract: PURPOSE: A pharmaceutical formulation containing simvastatin and olmesartan is provided to effectively treat hypertension and hyperlipidemia and prevent complication with less side effects. CONSTITUTION: A pharmaceutical formulation contains a immediate release compartment containing a simvastatin as a pharmacologically active ingredient, its isomer or its pharmaceutically acceptable salt, and a sustained release compartment containing olmesartan, its prodrug or its pharmaceutically acceptable salt. The olmesartan prodrug is olmesartan medoxomil. The sustained release compartment is coated containing osmotic regulator with semi-permeable film coating agent.
Abstract translation: 目的：提供含辛伐他汀和奥美沙坦的药物制剂，以有效治疗高血压和高脂血症，并预防并发症，减少副作用。 组成：药物制剂含有含有辛伐他汀作为药理活性成分，其异构体或其药学上可接受的盐的缓释隔室，以及含有奥美沙坦，其前药或其药学上可接受的盐的缓释隔室。 奥美沙坦前药是奥美沙坦酯。 含有渗透调节剂的半透膜包衣剂的缓释隔室被涂覆。
-
Patent Agency Ranking
公开(公告)号：KR1020090114329A
公开(公告)日：2009-11-03
申请号：KR1020090037381
申请日：2009-04-29
Applicant: 한올바이오파마주식회사
CPC classification number: A61K45/06
Abstract: PURPOSE: A pharmaceutical formulation containing immediate release atorvastatin and sustained release olmesartan is provided to treat coronary artery disease and maximize body absorption of drug. CONSTITUTION: A pharmaceutical formulation contains immediate release compartment of atorvastatin and sustained release compartment of olmesartan. The olmesartan is its isomer, its pharmaceutically acceptable salt, or its prodrug. An olmesartan prodrug is olmesartan medoxomil.
Abstract translation: 目的：提供含有立即释放阿托伐他汀和持续释放奥美沙坦的药物制剂，用于治疗冠状动脉疾病并使药物的身体吸收最大化。 构成：药物制剂含有阿伐他汀和奥美沙坦持续释放隔离区的立即释放区。 奥美沙坦是其异构体，其药学上可接受的盐或其前药。 奥美沙坦前药是奥美沙坦酯。
-
公开(公告)号：KR1020090107958A
公开(公告)日：2009-10-14
申请号：KR1020090030619
申请日：2009-04-09
Applicant: 한올바이오파마주식회사
IPC: A61K31/435 , A61K31/41 , A61K9/52 , A61P9/12
CPC classification number: A61K31/4178 , A61K9/209 , A61K9/28 , A61K9/48 , A61K31/4418 , A61K47/00 , A61K47/30
Abstract: PURPOSE: A pharmaceutical formulation for treating cardiovascular diseases is provided to uniformly maintain blood pressure and use for suppressing blood pressure when a hypertension patient sleeps. CONSTITUTION: A pharmaceutical formulation for treating cardiovascular disease contains immediate release compartment and sustained release compartment. The immediate release compartment contains an olmesartan as a pharmacologically active ingredient, its pharmaceutically acceptable salt or its prodrug. The sustained release compartment contains an amlodipine as a pharmacologically active ingredient, or its pharmaceutically acceptable salt.
Abstract translation: 目的：提供一种治疗心血管疾病的药物制剂，以均匀维持血压，并在高血压患者睡眠时用于抑制血压。 构成：用于治疗心血管疾病的药物制剂包含立即释放隔室和缓释隔室。 立即释放隔室含有奥美沙坦作为药理学活性成分，其药学上可接受的盐或其前药。 缓释隔室含有氨氯地平作为药理活性成分或其药学上可接受的盐。
-
公开(公告)号：KR1020090076827A
公开(公告)日：2009-07-13
申请号：KR1020090001170
申请日：2009-01-07
Applicant: 한올바이오파마주식회사
IPC: C07D213/80 , A61K31/4406 , A61P3/10 , A61P3/06
CPC classification number: C07D213/80
Abstract: A N,N-dimethyl imidodicarbonimidic diamide nicotinate is provided to improve manufacturing with low toxicity and prevent and treat diabetes and complication of diabetes. A metformin nicotinic acid salt is denoted by the chemical formula 1. In the chemical formula 1, n is 1 or 2. The metformin nicotinic acid salt is anhydrous or hydrous state. A method for manufacturing the metformin nicotinic acid salt comprises: a step of reacting 1-4 mole equivalent of inorganic base in sodium hydroxide or potassium hydroxide in water or organic solvent to produce metformin free base of the chemical formula 3; and a step of removing inorganic salt in the compound of the chemical formula 3 and reacting with 1-4 mole equivalent of nicotinic acid of the chemical formula 4. The organic solvent is methanole, ethanol, isopropanol, acetone, or acetonitrile. A pharmaceutical composition comprises the metformin nicotinic acid salt of the chemical formula 1 as an active ingredient.
Abstract translation: 提供N，N-二甲基亚氨基二亚胺二酰胺烟酸酯以改善低毒制剂，预防和治疗糖尿病和糖尿病并发症。 二甲双胍烟酸盐由化学式1表示。在化学式1中，n为1或2.二甲双胍烟酸盐为无水或含水状态。 制备二甲双胍烟酸盐的方法包括：使1-4摩尔当量无机碱在氢氧化钠或氢氧化钾在水或有机溶剂中反应以制备化学式3的二甲双胍游离碱的步骤; 以及除去化学式3的化合物中的无机盐并与1-4摩尔当量的化学式4的烟酸反应的步骤。有机溶剂是甲醇，乙醇，异丙醇，丙酮或乙腈。 药物组合物包含化学式1的二甲双胍烟酸盐作为活性成分。
-
6.发明公开
公开(公告)号：KR1020090031314A
公开(公告)日：2009-03-25
申请号：KR1020080092366
申请日：2008-09-19
Applicant: 한올바이오파마주식회사
IPC: C07C279/26 , C07C279/20 , C07C55/14
CPC classification number: C07C279/26 , C07C55/08 , C07C55/12 , C07C55/14 , C07C59/245
Abstract: Metformin dicarboxylate is provided to improve physical and chemical properties including solubility, stability, non-hygroscopicity and anti-adhesive properties, and low toxicity and to ensure effects in the prevention and treatment of not only diabetes and its complications in patients with so-called metabolic syndromes such as diabetes, obesity, hyperlipidemia, fatty liver, coronary artery disease, osteoporosis, and polycystic ovary syndromes. Metformin dicarboxylate is represented by the following formula 1, wherein X is -(CH2)n- (n = 1, 3 or 4) or -CH2-CH(OH)-. A method for preparing metformin dicarboxylate represented by the formula 1 comprises the steps of: allowing 2-4 molar equivalents of metformin hydrochloride of the following formula 2 to react with 2-4 molar equivalents of inorganic alkali in water, organic solvent or a mixture thereof to produce a metformin free-base of the following formula 3, and then allowing the metformin free-base to react with 1 molar equivalent of dicarboxylic acid of the following formula 4.
Abstract translation: 提供二甲双胍二羧酸盐以改善物理和化学性质，包括溶解性，稳定性，非吸湿性和抗粘连性，以及低毒性，并确保不仅预防和治疗所谓代谢的患者的糖尿病及其并发症的作用 综合征如糖尿病，肥胖症，高脂血症，脂肪肝，冠状动脉疾病，骨质疏松症和多囊卵巢综合征。 二甲双胍二羧酸酯由下式1表示，其中X是 - （CH 2）n - （n = 1,3或4）或-CH 2 -CH（OH） - 。 由式1制备的二甲双胍二羧酸盐的方法包括以下步骤：使2-4摩尔当量的下式2的二甲双胍盐酸盐与2-4摩尔当量的无机碱在水，有机溶剂或其混合物中反应 产生下式3的二甲双胍游离碱，然后使二甲双胍游离碱与1摩尔当量的下式4的二羧酸反应。
-
7.发明授权
公开(公告)号：KR101104912B1
公开(公告)日：2012-01-12
申请号：KR1020090001170
申请日：2009-01-07
Applicant: 한올바이오파마주식회사
IPC: C07D213/80 , A61K31/4406 , A61P3/10 , A61P3/06
CPC classification number: C07D213/80
Abstract: 본 발명은 N,N-디메틸 이미도디카르본이미딕 디아미드의 니코틴산염, 그의 제조방법 및 그를 포함하는 약제학적 조성물에 관한 것으로서, 더욱 상세하게는 용해도, 안정성, 비흡습성, 정제 제형으로서의 가공성 등의 물리화학적 성질이 개선되었을 뿐 아니라, 독성이 낮고, N,N-디메틸 이미도디카르본이미딕 디아미드가 본질적으로 발휘하는 약화학적 특성인 당뇨 및 당뇨병, 비만증, 고지혈증, 지방간, 관상동맥질환, 골다공증, 다낭성 난소증후군 등이 복합적으로 나타나는 이른바 대사성 증후군을 지닌 자들의 당뇨병 치료, 당뇨병자의 합병증의 근본 핵심 원인 물질인 중성 지질 저하 작용에 의한 합병증 예방 및 치료 그리고 p53 유전자가 결여된 암, 근육통, 근육세포 독성 및 횡문근 융해의 예방 및 치료 효과를 더욱 증가시켜줄 수 있는 치료제로서 유� ��한 N,N-디메틸 이미도디카르본이미딕 디아미드의 니코틴산염, 그의 제조방법과 그의 약제학적 조성물에 관한 것이다.
메트포르민, 메트포르민 니코틴산염, 메트포르민 이니코틴산염, N,N-디메틸 이미도디카르본이미딕 디아미드, 니코틴산염, 결정성 산부가염, 당뇨병, 대사성증후군
-
-
-
-
-
-
Search Results
7
records
(took 0.025 seconds)
